Effectiveness of tocilizumab in non-intubated cases with COVID-19: a systematic review and meta-analysis
- 10 May 2023
- journal article
- research article
- Published by Springer Science and Business Media LLC in Infection
- Vol. 51 (6), 1619-1628
- https://doi.org/10.1007/s15010-023-02047-2
Abstract
Purpose Tocilizumab, a monoclonal IL-6 receptor blocker, is an effective agent for severe-to-critical cases of COVID-19; however, its target patients for the optimum use need to be detailed. We performed a systematic review and meta-analysis to define its effect among severely ill but non-intubated cases with COVID-19. Methods We searched PubMed, Scopus, Web of Science, MEDLINE, Cochrane Central Register of Controlled Trials (CENTRAL), Medrxiv, and Biorxiv until February 13, 2022, for non-intubated cases, and included randomized-controlled trials (RCT) based on bias assessment. The primary outcomes were the requirement of invasive mechanical ventilation and mortality. Random effect and fixed-effect models were used. The heterogeneity was measured using the χ2 and I2 statistics, with χ2 p ≤ 0.05 and I2 ≥ 50% indicating the presence of significant heterogeneity. We registered the study to the International Prospective Register of Systematic Reviews (PROSPERO) with the registration number CRD42021232575. Results Among 261 articles, 11 RCTs were included. The pooled analysis of the 11 RCTs demonstrated that the rate of mortality was significantly lower in the tocilizumab group than in the control group (20.0% and 24.2%, OR: 0.84, 95% CI 0.73–0.96, and heterogeneity I2 = 0%. p = 0.82.). The mechanical ventilation rate was lower in the tocilizumab group than the control group (27% vs 35.2%, OR: 0.76, 95% CI 0.67–0.86, and heterogeneity I2 = 6%. p = 0.39). Conclusion Among non-intubated severe COVID-19 cases, tocilizumab reduces the risk of invasive mechanical ventilation and mortality compared to standard-of-care treatment.Keywords
This publication has 29 references indexed in Scilit:
- Preventing Opioid-Induced ConstipationJAMA Internal Medicine, 2020
- Efficacy of tocilizumab in COVID‐19: A systematic review and meta‐analysisJournal of Medical Virology, 2020
- Longitudinal analyses reveal immunological misfiring in severe COVID-19Nature, 2020
- Appropriate use of tocilizumab in COVID-19 infectionInternational Journal of Infectious Diseases, 2020
- Tocilizumab for severe COVID-19: a systematic review and meta-analysisInternational Journal of Antimicrobial Agents, 2020
- Characteristics of and Important Lessons From the Coronavirus Disease 2019 (COVID-19) Outbreak in ChinaJAMA, 2020
- The Novel Coronavirus Originating in Wuhan, ChinaJAMA, 2020
- A Novel Coronavirus from Patients with Pneumonia in China, 2019The New England Journal of Medicine, 2020
- ROBINS-I: a tool for assessing risk of bias in non-randomised studies of interventionsBMJ, 2016